Carregant...
Safety and efficacy of obinutuzumab in Chinese patients with B-cell lymphomas: a secondary analysis of the GERSHWIN trial
BACKGROUND: Patients with relapsed/refractory B-cell lymphomas have limited treatment options. GERSHWIN is an open-label, single-arm, phase Ib study of obinutuzumab monotherapy in Chinese patients with histologically documented CD20(+) relapsed/refractory chronic lymphocytic leukemia (CLL), diffuse...
Guardat en:
| Publicat a: | Cancer Commun (Lond) |
|---|---|
| Autors principals: | , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5993131/ https://ncbi.nlm.nih.gov/pubmed/29843792 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40880-018-0300-5 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|